Scientists at Biocontrol, leading the world in developing new treatments to cure serious antibiotic-resistant infections, have secured a £250,000 investment from The Capital Fund. This is part of a funding round totalling £500,000, with the rest of the funding coming from existing Biocontrol shareholders. BC Capital, Biocontrol's financial advisors provided crucial support throughout the funding process.

Ed Simpson, Investment Manager at The Capital Fund, said: "We are delighted to be working with Biocontrol. David Harper's team have developed some amazing products with clearly enormous potential. This investment is particularly pleasing for us as the end benefits, not just for the company and its backers but for millions of patients worldwide, could be very significant. We look forward to following Biocontrol's progress with interest."

Launched in 2002, The Capital Fund is a £50 million venture capital fund that backs fast-growing, small and medium-sized enterprises in Greater London. To date, the Fund has made over 50 investments in London-based companies and was named Regional Venture Capital Fund of the Year at the Investor Allstars Awards 2005.

Biocontrol Limited is a UK-based company that holds a leading position in the development of biological antibiotics based on bacteriophages, naturally occurring viruses that target and destroy bacteria. The company's lead product is currently in clinical trials against ear infections caused by Pseudomonas aeruginosa.